Good to see insights on management of prostate cancer from Prof Lisa Hovarth, A/Prof Jeff Goh and David Pook.

Dr David Pook David Pook on hot topics from 2022: more is not always better, when more drugs does not mean better outcomes | Best of GU Evening Symposium | ANZUP USANZ Australia & New Zealand Urological Nurses Society

Now online Clinical Cancer Research - Phase IB study ipatasertib plus rucaparib in mCR #prostatecancer post-NHA. No evidence of synergistic or additive antitumor activity. No clear signal of benefit in biomarker +ve populations either My take: Still no role for targeting PI3K pathway in mCRPC

#ANZUP23 ASM is happening tomorrow! This is your final opportunity to register for the premier GU cancer meeting in the region. Secure your spot now at anzup.org.au/registration-2/. We look forward to seeing you at Melbourne Convention Centre.

New to the #ANZUP23 ASM, The Perfect Pitch workshop is chaired by Shankar Siva and Ciara Conduit. It is designed to discuss how to pitch an idea and how to bring new concepts forward for idea development, which could potentially move on to a fully fledged clinical trial.

Laura Porter discussing tumour microenvironment manipulation with carboplatin to improve uptake of Lewis Y targeted CAR T cells into prostate tumours. Keeping the dream of effective immunotherapy in prostate cancer alive. #ANZUP23

.Dr. Darren Feldman on Challenges & Pitfalls in #GCT Management | #ANZUP23 #testiscancer

Mitch Lawrence explaining how high dose testosterone can be used to treat prostate cancer and how his team are investigating this in PDX models #ANZUP23

Liz Liow presenting KRAB data (Australian real world kidney cancer data) ANZUP #ANZUP23 at best of the best oral abstract session WEHI (Walter and Eliza Hall Institute) Daniel Heng

Gem/cis & nivolumab achieves significant PFS & OS in 1st line UC . Maintenance avelumab = 25% ⬆️ in OS, but not all pts get there. Better disease control during the chemo phase and competitive OS HR will be attractive to patients. news.bms.com/news/corporate…

JUST IN: some news in metastatic bladder cancer combinations via ⁦Reuters⁩ reut.rs/46Gga8h reut.rs/46Gga8h

Pleased to share The Lancet Oncology LENVA-PEMBRO across RCC variant histologies: papillary RCC, unclRCC and chromophobe RCC … interim ESMO - Eur. Oncology #ESMO22 and final Chung-Han Lee 李宗翰, MD/PhD ASCO #ASCO23 full text: authors.elsevier.com/a/1hP1c5EIIgLp… Thanks to all who change rareRCC pts Tx!

Very sad what we’re seeing around the World #endhate

BrCAAway study reports 39m rPFS with Abi+Olap in mCRPC with HRD, 8.4m for Abi and 14m for Olap. Possible synergy but less than 1/3 of monotherapy pts crossed over. 50% of pts screened for HRD were +ve which is far higher than we see in clinic. #GU24

CONTACT-02 Study showed improvement in rPFS in CRPC patients with soft tissue disease from 4.2m to 6.3m with Cabo/Atezo vs ARSI switch. Lots of questions about the ethics of randomising a patient with liver mets to ARSI switch. I would not be comfortable doing this. #GU24

Delving into the ENZAMET trial: Radiographic progression in mHSPC may occur without PSA elevation, challenging conventional monitoring methods. The study underscores the complexity of disease progression. #ProstateCancer Ian Davis (Bluesky @profiand) Christopher Sweeney, MBBS ASCO #GU24 OncoAlert

Great ANZUP poster ASCO #GU24 Baseline disease characteristics of participants enrolled on #ENZARAD & #DASLHiCaP Congrats Dr. Tamim Niazi Christopher Sweeney, MBBS Paul Nguyen & Scott Williams NHMRC CTC The PCCTC CancerTrialsIreland 🌈 CCTG Memorial Sloan Kettering Cancer Center Astellas Pharma US Bayer AG

KN-564 shows significant improvement in overall survival in RCC with 12m of adjuvant pembro with HR 0.62. Meanwhile the Nivo arm of CM-914 is negative. Unsure if this is due to differences in drug activity or just duration of treatment. #GU24

Great to see ANZUP #UNICAB Study poster ASCO #GU24 presented by David Pook. Well done to entire team for their ongoing hard work #kidneycancer #improvingoutcomes #BaCT Peter Mac Cancer Centre @IpsenGroup Cancer Australia Craig Gedye Ian Davis (Bluesky @profiand)